GlaxoSmithKline says annual profits triple to £5.26 bln

February 7, 2012

British drugmaker GlaxoSmithKline said Tuesday that net profits more than tripled in 2011 compared with the previous year, as large efficiency savings offset falling revenues.

Earnings after tax surged to £5.261 billion (6.34 billion euros, $8.32 billion) in 2011, which compared with £1.634 in the previous year, GSK said in a results statement.

GSK added that it bounced back into the black in the fourth quarter, or three months to December, when net profit hit £1.25 billion. That compared with a net loss of £690 million a year earlier, when GSK took £2.17 billion in legal charges linked to its former diabetes drug Avandia.

The drug was pulled from European shelves in 2010 on fears that it increased the risk of heart attack and strokes.

GSK added Tuesday that revenues fell to £27.387 billion last year, reflecting lower sales of Avandia, anti-viral medicine Valtrex and pandemic flu vaccines.

Chief executive Andrew Witty cautioned about the fragile global economic outlook but predicted the group would increase shareholder returns this year as a result of ongoing efficiency measures.

"As we go into 2012, we are mindful of the potential pressures we face given the current global political and economic environment," Witty said in the release.

"However, we continue to expect to drive further shareholder returns as we seek to grow sales across our broadly based business and improve operational leverage and financial efficiency to deliver strong cash generation.

"We will also continue to invest appropriately in the business to generate sustainable and profitable sales growth," he added.

In early afternoon deals, GSK's share price fell 1.87 percent to 1,393 pence on London's FTSE 100 index of leading companies, which was 0.68 percent lower at 5,852.10 points.

Witty, who took the top job in 2008, has sought to diversify into consumer health care, emerging markets and biotechnology, as the pharmaceuticals industry faces competition from generic drugmakers.

Explore further: GlaxoSmithKline reports return to profit in second quarter

Related Stories

GlaxoSmithKline reports return to profit in second quarter

July 26, 2011
British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

GlaxoSmithKline posts rising Q3 profits

October 26, 2011
British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

Drugs firm GSK eyes India acquisitions: chief executive

October 3, 2011
British drugmaker GlaxoSmithKline is in the market to buy assets in India at a total cost of up to $2.0 billion (1.5 billion euros), its chief executive said in an interview published on Monday.

British drugs firm GSK settles US drug disputes for $3.0 bln

November 3, 2011
GlaxoSmithKline said on Thursday it had agreed to pay $3.0 billion (2.2 billion euros) to settle long-running disputes with the US government over how the British pharmaceuticals group marketed and developed drugs.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.